Protocols

Braeburn Pharma files for $150M IPO; Tiziana in-licenses Novimmune antibody

• Braeburn Pharmaceuticals, which markets and develops treatments for opioid addiction, has filed for a $150 million IPO. The offering notes that Apple Tree Partners has agreed to buy $40 million in stock. Here’s the S-1.

• The UK’s Tiziana Life Sciences has bagged a global license for the IL-6R antibody NI-1201 from Novimmune. The companies did not spell out the financial terms of the deal. “We view NI-1201 as a potential game-changer for addressing the high unmet need of autoimmune and inflammatory diseases” commented Gabriele Cerrone, Chairman of Tiziana Life Sciences. “The acquisition of NI-1201 not only strengthens our business strategy of developing novel fully human mAbs to treat life-threatening inflammatory diseases such as non-alcoholic steatohepatitis (NASH) and rheumatoid arthritis, but expands our potential to leverage the pioneering work we are doing with foralumab, the oral anti-CD3 mAb to treat autoimmune and inflammatory diseases.”

• Cambridge, MA-based Voyager Therapeutics $VYGR named Jane Pritchett Henderson as senior vice president and chief financial officer.

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017